Bottom line
MISCX vs BKLC: the short answer
MISCX (BNY Mellon Small Cap Multi-Strategy Fund) and BKLC (BNY Mellon US Large Cap Core Equity ETF) are both mutual funds.
But BKLC is far broader, holding 510 positions to 153 for MISCX, so beyond the top names it adds exposure MISCX doesn't have.
BKLC is cheaper at 0% vs 1.34% — a difference of $134 a year per $10,000 invested.
Over five years, BKLC returned +14.4% a year vs +6.9% for MISCX (reporting dates differ).
Updated Nov 19, 2026
MISCX vs BKLC side by side
| MISCX | BKLC | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | BNY Mellon / Dreyfus | BNY Mellon / Dreyfus |
| Category | Alternatives | Large Blend |
| Expense ratio | 1.34% | 0% |
| Annual cost per $10k | $134 | $0 |
| 10-yr cost on $10k (prospectus) | — | — |
| Max front load | — | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +8.7% | +18.1% |
| 5-yr return (annualized) | +6.9% | +14.4% |
| 10-yr return (annualized) | +7.7% | — |
| Best quarter | — | +12.5% |
| Worst quarter | — | −17.1% |
| Net assets (fund) | $130.3M | $5.5B |
| Number of holdings | 153 | 510 |
| Portfolio turnover | 75% | 2% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
MISCX and BKLC share none of their top holdings.
MISCX top 10
- Dreyfus Institutional Preferred Money Market Funds — 2.33%
- Baldwin Insurance Group Inc (the) — 2.11%
- Bel Fuse Inc — 2.11%
- Kulicke And Soffa Industries Inc — 2.04%
- Guardant Health Inc — 1.80%
- Herc Holdings Inc — 1.77%
- Sensata Technologies Holding Plc — 1.77%
- Myr Group Inc — 1.74%
- Repligen Corp — 1.74%
- Construction Partners Inc — 1.64%
BKLC top 10
- Nvidia Corp — 7.23%
- Apple Inc — 6.81%
- Microsoft Corp — 5.26%
- Amazon.com Inc — 4.02%
- Alphabet Inc — 3.19%
- Broadcom Inc — 2.79%
- Alphabet Inc — 2.79%
- Meta Platforms Inc — 1.88%
- Tesla Inc — 1.60%
- Eli Lilly & Company — 1.50%
FAQ
What is the difference between MISCX and BKLC?
Which is cheaper, MISCX or BKLC?
Should I own both MISCX and BKLC?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.